FGFR3 and skeletal dysplasia: Ongoing clinical trials have shown that in patients with achondroplasia, in which skeletal dysplasia is caused by a constitutively active form of FGFR3, stimulation of NPR2 by subcutaneous injection of a hydrolysis-resistant analog of CNP increases bone length (Klag and Horton, 2016).